Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001209191-14-050677
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-08-05 17:39:00
Reporting Period:
2014-08-05
Filing Date:
2014-08-05
Accepted Time:
2014-08-05 17:39:00
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1501756 Avalanche Biotechnologies Inc. AAVL Biological Products, (No Disgnostic Substances) (2836) 205258327
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
872589 Regeneron Pharmaceuticals Inc 777 Old Saw Mill River Road
Tarrytown NY 10591
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-08-05 689,655 $0.00 689,655 No 4 C Direct
Common Stock Acquisiton 2014-08-05 531,208 $0.00 1,220,863 No 4 C Direct
Common Stock Acquisiton 2014-08-05 588,235 $17.00 1,809,098 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2014-08-05 689,655 $0.00 689,655 $0.00
Common Stock Series B Preferred Stock Disposition 2014-08-05 531,208 $0.00 531,208 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Direct
Footnotes
  1. The Series A Preferred Stock converted into Avalanche Biotechnologies, Inc. common stock on a one-for-one basis and had no expiration date.
  2. The Series B Preferred Stock converted into Avalanche Biotechnologies, Inc. common stock on a one-for-one basis and had no expiration date.